Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Corange's $110 mil. equity investment in CellPro will give the Boehringer-Mannheim parent a 15% ownership interest in the Bothell, Wash.-based cell-separation technology company. The equity purchase is part of a potential $220 mil. Corange will invest in CellPro under an agreement announced Dec. 6. CollPro and Corange will collaborate to develop and market stem cell selection products for therapeutic applications outside of North America. Corang's will also license worldwide rights to diagnostic products using CellPro's cell-selection technology in exchange for royalties. CellPro expects to submit a premarketing approval application to FDA before the end of the year for its CEPRATE SC stem cell separation device for use in bone marrow transplantation to treat cancer. The company already is selling a CEPRATE system for research use in the U.S. and began marketing the system in Europe in September. Boehringer-Mannheim said it plans to develop the CEPRATE technology for bone marrow transplantation, high dose chemotherapy, autoimmune diseases and gene therapy. The device is in Phase I/II trials for peripheral stem cell transplantation, high dose chemotherapy and allogeneic bone marrow transplantation. CellPro expects to begin trials in early 1994 in liver transplant patients using donor stem cells to prevent transplant rejection. A longer-term project is using bone marrow transplants to cure autoimmune diseases such as lupus and rheumatoid arthritis. The CEPRATE system has been used in several gene therapy trials involving transduction of stem cells. The pioneering ADA deficiency trials, for instance, use the CellPro device. Boehringer-Mannheim says it has a gene therapy research program, although it is not among the first wave of companies to collaborate in human clinical trials. Boehringer-Mannheim expects to develop CellPro's in vitro diagnostic technologies for use in fetal cell diagnostics, cancer and selected infectious diseases. CellPro expects to begin clinical trials of a cancer diagnostic and a fetal cell diagnostic using cells extracted from maternal blood within a year, the company said. Corange will pay $50 mil. for 8% of Cellpro (1.2 mil. newly- issued shares) upon closing of the deal and $60 mil. for an additional 7% of the company 15 months after closing of the deal. CellPro will also receive a $10 mil. signing fee and R&D/milestone payments of up to $100 mil. The hefty premium to be paid by Corange is in keeping with other recent buy-ins involving cell separation companies. Sandoz paid more than double the market value with its $392 mil. purchase of a controlling interest in SyStemix in late 1991 ("The Pink Sheet" Dec. 23, 1991, p. 3). Rhone-Poulenc Rorer paid a 58% premium for 37% of Applied Immune Sciences in June ("The Pink Sheet" June 7, p. 10). Corange is valuing CellPro at a 50% premium to its recent per share price of 28-3/4. Under its new CEO Max Link, Corange is building a portfolio of biotechnology investments similar to that established by Sandoz during Link's tenure there. In late October, the company committed up to $131 mil. in equity and R&D support to the monoclonal antibody research firm Protein Design Labs ("The Pink Sheet" Nov. 1, T&G-10). Boehringer-Mannheim is also looking to acquire gene therapy and xenotransplantation technologies, the company said. Boehringer-Mannheim Therapeutics "operates the largest biotechnology facility in Europe" in Penzberg, Germany, the company says. Sales for the therapeutics division totaled $864 mil. in 1992. Boehringer-Mannheim Diagnostics "is the second largest producer of in vitro diagnostics products and services in the world," with sales of $1.8 bil. in 1992. The agreement is subject to antitrust review "and other normal closing conditions to sales of equity in private placement transactions," the companies said. The deal is expected to close in the first quarter of 1994.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts